Published • loading... • Updated
Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology
The deal gives BMS worldwide rights outside Greater China and includes up to $15.2 billion in milestones and royalties, the companies said.
- On Tuesday, May 12, 2026, Bristol Myers Squibb and Hengrui Pharma announced a global strategic collaboration to advance 13 early-stage programs in oncology, hematology, and immunology.
- The companies intend to leverage complementary capabilities, combining Hengrui's discovery engine and efficient early-stage development expertise with BMS's research, regulatory, and commercial scale.
- Under the agreement, BMS will pay Hengrui up to $950 million upfront and contingent payments, with total potential value of approximately $15.2 billion; BMS secures exclusive worldwide rights outside Chinese mainland, Hong Kong SAR, and Macau SAR.
- "This broad strategic collaboration reflects a highly synergistic collaboration," said Frank Jiang, Executive Vice President and Chief Strategy Officer of Hengrui Pharma, while Robert Plenge, Executive Vice President and Chief Research Officer, Bristol Myers Squibb, noted support for "driving top tier growth in the next decade."
- The transaction is expected to close in the third quarter of 2026, subject to review under the Hart Scott Rodino Antitrust Improvements Act and other customary closing conditions.
Insights by Ground AI
22 Articles
22 Articles
The Courier-Tribune+17 Reposted by 17 other sources
Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology
Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide
Hengrui Soars After $15B Innovative Drug Deal with BMS
Shares of the Chinese pharmaceutical company surged following the announcement that it has entered into a deal valued at up to $15.2 billion with a major U.S. pharmaceutical firm to co-develop innovative medications. The Shanghai-listed stock soared by 4.8%, closing at CNY56.11 (about $8.25), after earlier hitting the daily trading limit of 10%. Its Hong Kong-listed counterpart also experienced significant gains, climbing as much as 16.2% before…
Coverage Details
Total News Sources22
Leaning Left3Leaning Right4Center7Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 21%
C 50%
R 29%
Factuality
To view factuality data please Upgrade to Premium
